Excited and grateful that we received $500K from an angel investor, enabling us to move forward with our CLIA LDT certification and prototype testing for CAL, a first-in-class precision cancer diagnostic instrument.
- cmargain
top of page
EMPIRI INC.
Search
Recent Posts
See AllWe are excited to share that Kyuson Yun, co-founder of Empiri, will be presenting at the 10x Genomics User Group Meeting. This is a...
EMPIRI's E-slice 3D tumor culture platform for real-time evaluation of therapeutic candidates can now be accessed through our store-front...
Funding to support a cancer diagnostic system to measure empirical treatment response Houston, TX, July 20, 2023 - EMPIRI, Inc., who is...
bottom of page
Comments